Last reviewed · How we verify
Pem only
Pem is a peptide-based immunotherapy that enhances anti-tumor immune responses, likely through peptide vaccine or checkpoint modulation mechanisms.
Pem is a peptide-based immunotherapy that enhances anti-tumor immune responses, likely through peptide vaccine or checkpoint modulation mechanisms. Used for Cancer (specific indication not publicly confirmed).
At a glance
| Generic name | Pem only |
|---|---|
| Also known as | Alimta: brand name of pemetrexed |
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific mechanistic details for 'Pem' from Asan Medical Center are limited in public literature, peptide-based therapeutics in Phase 3 development typically work by activating T-cell responses against tumor-associated antigens or modulating immune checkpoint pathways. The exact molecular target and mechanism require confirmation from clinical trial protocols.
Approved indications
- Cancer (specific indication not publicly confirmed)
Common side effects
Key clinical trials
- Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG (PHASE2)
- Impact of a Human Origin Heat Inactivated Probiotic-Lactobacillus Paracasei D3.5 (LpD3.5) as Dietary Supplement on Gut Mucin and Intestinal Permeability in Adults With IBD (NA)
- S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer (NA)
- Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma
- Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
- Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization (NA)
- MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers (PHASE2)
- M1231 in Participants With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |